InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.410 -0.055 (-11.83%)+
Announcement
Release
2 Sep 2025 1:07PM
Price at Release
$0.465
Full Release
download
Summary
Cambium Bio Limited announced a licensing deal with Keke Medtech, granting them exclusive rights to develop and commercialize the company's fibrin biologic for dental and oral wound-healing applications. The deal includes a US$250,000 upfront payment and US$1.75 million in development milestones, with royalties on net sales. Keke Medtech will cover all development costs, aiming for clinical trials within 24 months. This agreement provides Cambium with non-dilutive funding, allowing them to focus on advancing their Elate Ocular® Phase 3 program while expanding their platform's applications.
Key Points
  • Cambium Bio signs a US$2.0M+ licensing deal with Keke Medtech.
  • The deal covers developing a fibrin biologic for dental and oral applications.
  • Financial terms include US$250,000 upfront and US$1.75 million in milestones.
  • Royalties on net sales are set at 10% for the first US$10M annually, then 13%.
  • The agreement is for US, Southeast Asia, Middle East, and Taiwan.
  • Keke will finance all related development costs.
  • Cambium retains focus on their Elate Ocular® Phase 3 program.
  • The deal provides strategic validation and non-dilutive funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.